Publications
Detailed Information
What is the most cost-effective strategy to screen for second primary colorectal cancers in male cancer survivors in Korea?
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Sang Min | - |
dc.contributor.author | Kim, Sun-Young | - |
dc.contributor.author | Earle, Craig C. | - |
dc.contributor.author | Jeong, Seung-Yong | - |
dc.contributor.author | Yun, Young Ho | - |
dc.date.accessioned | 2012-05-23T01:26:01Z | - |
dc.date.available | 2012-05-23T01:26:01Z | - |
dc.date.issued | 2009-07-07 | - |
dc.identifier.citation | WORLD JOURNAL OF GASTROENTEROLOGY; Vol.15 25; 3153-3160 | ko_KR |
dc.identifier.issn | 1007-9327 | - |
dc.identifier.uri | https://hdl.handle.net/10371/76294 | - |
dc.description.abstract | AIM: To identify a cost-effective strategy of second primary colorectal cancer (CRC) screening for cancer survivors in Korea using a decision-analytic model. METHODS: A Markov model estimated the clinical and economic consequences of a simulated 50-year-old male cancer survivors` cohort, and we compared the results of eight screening strategies: no screening, fecal occult blood test (FOBT) annually, FOBT every 2 years, sigmoidoscopy every 5 years, double contrast barium enema every 5 years, and colonoscopy every 10 years (COL10), every 5 years (COL5), and every 3 years (COL3). We included only direct medical costs, and our main outcome measures were discounted lifetime costs, life expectancy, and incremental cost-effectiveness ratio (ICER). RESULTS: In the base-case analysis, the non-dominated strategies in cancer survivors were COL5, and COL3. The ICER for COL3 in cancer survivors was $5593/life-year saved (LYS), and did not exceed $10000/LYS in one-way sensitivity analyses. If the risk of CRC in cancer survivors is at least two times higher than that in the general population, COL5 had an ICER of less than $10500/LYS among both good and poor prognosis of index cancer. If the age of cancer survivors starting CRC screening was decreased to 40 years, the ICER of COL5 was less than $7400/LYS regardless of screening compliance. CONCLUSION: Our study suggests that more strict and frequent recommendations for colonoscopy such as COL5 and COL3 could be considered as economically reasonable second primary CRC screening strategies for Korean male cancer survivors. (C) 2009 The WIG Press and Baishideng. All rights reserved. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | W J G PRESS | ko_KR |
dc.subject | Cost-effectiveness | ko_KR |
dc.subject | Second primary colorectal cancer | ko_KR |
dc.subject | Cancer survivor | ko_KR |
dc.subject | Screening | ko_KR |
dc.title | What is the most cost-effective strategy to screen for second primary colorectal cancers in male cancer survivors in Korea? | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 박상민 | - |
dc.contributor.AlternativeAuthor | 김선영 | - |
dc.contributor.AlternativeAuthor | 정승용 | - |
dc.contributor.AlternativeAuthor | 윤영호 | - |
dc.identifier.doi | 10.3748/wjg.15.3153 | - |
dc.citation.journaltitle | WORLD JOURNAL OF GASTROENTEROLOGY | - |
dc.description.citedreference | Park SM, 2007, J CLIN ONCOL, V25, P4835, DOI 10.1200/JCO.2006.10.3416 | - |
dc.description.citedreference | Jung KW, 2007, J KOREAN MED SCI, V22, pS5 | - |
dc.description.citedreference | *WORLD BANKS GLOB, 2007, WORLD DEV IND 2007 | - |
dc.description.citedreference | Smith RA, 2006, CA-CANCER J CLIN, V56, P11 | - |
dc.description.citedreference | Choe JW, 2007, J GASTROEN HEPATOL, V22, P1003, DOI 10.1111/j.1440-1746.2007.04774.x | - |
dc.description.citedreference | SMITH RA, 2006, CA CANC J CLIN, V56, P49 | - |
dc.description.citedreference | *MIN HLTH WELF KOR, 2006, NAT CANC SCREEN PROG | - |
dc.description.citedreference | Ladabaum U, 2005, GASTROENTEROLOGY, V129, P1151, DOI 10.1053/j.gastro.2005.07.059 | - |
dc.description.citedreference | Dikshit RP, 2005, CANCER, V103, P2326, DOI 10.1002/cncr.21051 | - |
dc.description.citedreference | SHIN HR, 2005, CANC RES TREAT, V37, P325 | - |
dc.description.citedreference | PARK SM, 2005, KOREA WORLD J GASTRO, V11, P1587 | - |
dc.description.citedreference | Eichler HG, 2004, VALUE HEALTH, V7, P518 | - |
dc.description.citedreference | Cotton PB, 2004, JAMA-J AM MED ASSOC, V291, P1713 | - |
dc.description.citedreference | Misra T, 2004, CAN J GASTROENTEROL, V18, P221 | - |
dc.description.citedreference | *NAT HLTH INS CORP, 2004, CONTR MED PRIC NAT H | - |
dc.description.citedreference | *NAT CANC I, 2004, SURV EP RES SEER | - |
dc.description.citedreference | *US DEP HHS, 2004, LIV CANC FIND NEW BA | - |
dc.description.citedreference | *NAT HLTH INS CORP, 2002, 2001 RES CLIN PRACT | - |
dc.description.citedreference | *US PREV SERV TASK, 2002, COL CANC SCREEN SUMM | - |
dc.description.citedreference | BAE JM, 2002, CANC RES TREAT, V34, P319 | - |
dc.description.citedreference | Lieberman DA, 2001, NEW ENGL J MED, V345, P555 | - |
dc.description.citedreference | Dong C, 2001, INT J CANCER, V93, P155 | - |
dc.description.citedreference | Kavic SM, 2001, AM J SURG, V181, P319 | - |
dc.description.citedreference | *NAT STAT OFF REP, 2001, ANN REP CAUS DEATH S | - |
dc.description.citedreference | HUNINK M, 2001, DECISION MAKING HLTH, P277 | - |
dc.description.citedreference | Anderson ML, 2000, AM J GASTROENTEROL, V95, P3418 | - |
dc.description.citedreference | Kim DH, 2000, J KOREAN MED SCI, V15, P675 | - |
dc.description.citedreference | Frazier AL, 2000, JAMA-J AM MED ASSOC, V284, P1954 | - |
dc.description.citedreference | Winawer SJ, 2000, NEW ENGL J MED, V342, P1766 | - |
dc.description.citedreference | Khandker RK, 2000, INT J TECHNOL ASSESS, V16, P799 | - |
dc.description.citedreference | Desch CE, 1999, J CLIN ONCOL, V17, P1312 | - |
dc.description.citedreference | Winawer SJ, 1999, GASTROINTEST ENDOSC, V49, pS63 | - |
dc.description.citedreference | KIM TS, 1999, KOREAN J GASTROINTES, V19, P887 | - |
dc.description.citedreference | Glick S, 1998, AM J ROENTGENOL, V170, P629 | - |
dc.description.citedreference | Rex DK, 1997, GASTROENTEROLOGY, V112, P24 | - |
dc.description.citedreference | SHIMBO T, 1994, INT J TECHNOL ASSESS, V10, P359 | - |
dc.description.citedreference | AHLQUIST DA, 1992, CANCER, V70, P1259 | - |
dc.description.citedreference | WAGNER JL, 1991, ANN INTERN MED, V115, P807 | - |
dc.description.citedreference | HIXSON LJ, 1991, GASTROINTEST ENDOSC, V37, P125 | - |
dc.description.citedreference | KIM KH, 1991, J KOREAN SURG SOC, V41, P215 | - |
dc.description.citedreference | EDDY DM, 1990, ANN INTERN MED, V113, P373 | - |
dc.description.citedreference | STRYKER SJ, 1987, GASTROENTEROLOGY, V93, P1009 | - |
dc.description.citedreference | EIDE TJ, 1978, CANCER, V42, P2839 | - |
dc.description.citedreference | MUTO T, 1975, CANCER, V36, P2251 | - |
dc.description.citedreference | SPRATT JS, 1962, JAMA-J AM MED ASSOC, V179, P337 | - |
dc.description.citedreference | JACKMAN RJ, 1951, SURG GYNECOL OBSTET, V93, P327 | - |
dc.description.tc | 2 | - |
- Appears in Collections:
- Files in This Item:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.